Trends and Contributing Factors for Prescribing Antipsychotics in Newly Diagnosed Parkinson’s Disease Patients: A Population-Based Study

References

• Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017;13(2):81–95. doi:10.1038/nrneurol.2016.200
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017. doi:10.1038/nrn.2017.62
   Web of Science ®Google Scholar
• Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov Disord. 2016;31(1):45–52. doi:10.1002/mds.26432
   PubMed Web of Science ®Google Scholar
• Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017;32(9):1264–1310. doi:10.1002/mds.27115
   PubMed Web of Science ®Google Scholar
• Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson’s disease. Expert Opin Investig Drugs. 2014;23(3):387–410. doi:10.1517/13543784.2014.869209
   PubMed Web of Science ®Google Scholar
• Safarpour D, Thibault DP, DeSanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015;85(5):413–419. doi:10.1212/wnl.0000000000001715
   Web of Science ®Google Scholar
• Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006;14(3):152–164. doi:10.1080/10673220600748486
   PubMed Web of Science ®Google Scholar
• Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. doi:10.1155/2014/656370
   PubMed Web of Science ®Google Scholar
• Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med. 1995;99(1):48–54. doi:10.1016/S0002-9343(99)80104-1
   Web of Science ®Google Scholar
• Rogers G, Davies D, Pink J, Cooper P. Parkinson’s disease: summary of updated NICE guidance. BMJ. 2017;358:j1951. doi:10.1136/bmj.j1951
   PubMed Web of Science ®Google Scholar
• Lutz UC, Sirfy A, Wiatr G, et al. Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders. Eur J Clin Pharmacol. 2014;70(12):1471–1476. doi:10.1007/s00228-014-1772-0
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA) Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. Department of Health and Human Services, U.S. Government; 2005. Available from: www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171.htm. Accessed February 6, 2005.
   Google Scholar
• Food and Drug Administration (FDA). Information for healthcare professionals—antipsychotics. Department of Health and Human Services, U.S. Government; 2008. Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm. Accessed February 6, 2005
   Google Scholar
• Banerjee S. The use of antipsychotic medication for people with dementia: time for action. 2009.
   Google Scholar
• Weintraub D, Chiang C, Kim HM, et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol. 2016;73(5):535–541. doi:10.1001/jamaneurol.2016.0031
   PubMed Web of Science ®Google Scholar
• Marras C, Gruneir A, Wang X, et al. Antipsychotics and mortality in Parkinsonism. Am J Geriatr Psychiatry. 2012;20(2):149–158. doi:10.1097/JGP.0b013e3182051bd6
   PubMed Web of Science ®Google Scholar
• de Lau LM, Verbaan D, Marinus J, van Hilten JJ. Survival in Parkinson’s disease. Relation with motor and non-motor features. Parkinsonism Relat Disord. 2014;20(6):613–616. doi:10.1016/j.parkreldis.2014.02.030
   Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;3:CD006504. doi:10.1002/14651858.CD006504.pub2
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Parkinson’s disease in adults. NICE guideline [NG71]; 2017.
   Google Scholar
• Herrmann N, Marras C, Fischer HD, Wang X, Anderson GM, Rochon PA. Management of neuropsychiatric symptoms in long-term care residents with Parkinson’s disease: a retrospective cohort study. Drugs Aging. 2013;30(1):19–22. doi:10.1007/s40266-012-0038-8
   Web of Science ®Google Scholar
• Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol. 2011;68(7):899–904. doi:10.1001/archneurol.2011.139
   PubMedGoogle Scholar
• Wang MT, Lian PW, Yeh CB, Yen CH, Ma KH, Chan AL. Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson’s disease. Mov Disord. 2011;26(9):1663–1669. doi:10.1002/mds.23719
   PubMed Web of Science ®Google Scholar
• Lyons RA, Jones KH, John G, et al. The SAIL databank: linking multiple health and social care datasets. BMC Med Inform Decis Mak. 2009;9:3. doi:10.1186/1472-6947-9-3
   PubMed Web of Science ®Google Scholar
• Robinson D, Schulz E, Brown P, Price C. Updating the read codes: user-interactive maintenance of a dynamic clinical vocabulary. J Am Med Inform Assoc. 1997;4(6):465–472. doi:10.1136/jamia.1997.0040465
   PubMed Web of Science ®Google Scholar
• Parkinson’s UK. The prevalence and incidence of Parkinson’s in the UK. Parkinson’s UK; 2017. Available from: https://www.parkinsons.org.uk/sites/default/files/2018-01/Prevalence%20%20Incidence%20Report%20Latest_Public_2.pdf. Accessed January, 25, 2018.
   Google Scholar
• Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165(16):1882–1888. doi:10.1001/archinte.165.16.1882
   PubMed Web of Science ®Google Scholar
• Leroi I, Voulgari A, Breitner JC, Lyketsos CG. The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry. 2003;11(1):83–91. doi:10.1097/00019442-200301000-00011
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251. doi:10.1016/0895-4356(94)90129-5
   PubMed Web of Science ®Google Scholar
• Mauri MC, Paletta S, Di Pace C. Hallucinations in the substance-induced psychosis. In: Hallucinations in Psychoses and Affective Disorders. Cham: Springer; 2018:57–83.
   Google Scholar
• Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387–392. doi:10.1001/archneur.60.3.387
   PubMedGoogle Scholar
• Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67(4):492–496. doi:10.1136/jnnp.67.4.492
   PubMed Web of Science ®Google Scholar
• Marras C, Austin PC, Bronskill SE, Diong C, Rochon PA. Antipsychotic drug dispensing in older adults with Parkinsonism. Am J Geriatr Psychiatry. 2018;26(12):1244–1257. doi:10.1016/j.jagp.2018.08.003
   Web of Science ®Google Scholar
• Marras C, Kopp A, Qiu F, et al. Antipsychotic use in older adults with Parkinson’s disease. Mov Disord. 2007;22(3):319–323. doi:10.1002/mds.21192
   PubMed Web of Science ®Google Scholar
• Rigby HB, Rehan S, Hill-Taylor B, Matheson K, Sketris I. Antipsychotic prescribing practices in those with Parkinsonism: adherence to guidelines. Can J Neurol Sci. 2017;44(5):603–606. doi:10.1017/cjn.2017.36
   Web of Science ®Google Scholar
• Vanacore N, Bianchi C, Da Cas R, Rossi M. Use of antiparkinsonian drugs in the Umbria region. Neurol Sci. 2003;24(3):221–222. doi:10.1007/s10072-003-0140-0
   Web of Science ®Google Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence‐based medicine review. Mov Disorders. 2019;34(2):180–198. doi:10.1002/mds.27602
   PubMed Web of Science ®Google Scholar
• Patel RS, Bhela J, Tahir M, Pisati SR, Hossain S. Pimavanserin in Parkinson’s disease-induced psychosis: a literature review. Cureus. 2019;11(7):e5257. doi:10.7759/cureus.5257
   PubMed Web of Science ®Google Scholar
• Taylor C, Marsh-Davies A, Skelly R, Archibald N, Jackson S. Setting up a clozapine service for Parkinson’s psychosis. BJPsych Adv. 2021;1–9. doi:10.1192/bja.2021.24
   Google Scholar
• Cotton CC, Farkas DK, Foskett N, et al. Risk of upper gastrointestinal bleeding and gastroduodenal ulcers in persons with schizophrenia: a Danish cohort study. Clin Transl Gastroenterol. 2019;10(2):e00005. doi:10.14309/ctg.0000000000000005
   Web of Science ®Google Scholar
• Marston L, Nazareth I, Petersen I, Walters K, Osborn DP. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open. 2014;4(12):e006135. doi:10.1136/bmjopen-2014-006135
   PubMed Web of Science ®Google Scholar
• Orayj K, Akbari A, Lacey A, Smith M, Pickrell O, Lane EL. Factors affecting the choice of first-line therapy in Parkinson’s disease patients in Wales: a population-based study. Saudi Pharm J. 2021;29(2):206–212. doi:10.1016/j.jsps.2021.01.004
   Web of Science ®Google Scholar
• Cooper C, Lodwick R, Walters K, et al. Observational cohort study: deprivation and access to anti-dementia drugs in the UK. Age Ageing. 2016;45(1):148–154. doi:10.1093/ageing/afv154
   Web of Science ®Google Scholar
• Mercer SW, Watt GC. The inverse care law: clinical primary care encounters in deprived and affluent areas of Scotland. Ann Fam Med. 2007;5(6):503–510. doi:10.1370/afm.778
   PubMed Web of Science ®Google Scholar
• Fonferko-Shadrach B, Lacey AS, White CP, et al. Validating epilepsy diagnoses in routinely collected data. Seizure. 2017;52:195–198. doi:10.1016/j.seizure.2017.10.008
   Web of Science ®Google Scholar